CytomX(US:CTMX) ZACKS·2025-11-07 01:01Core Insights - CytomX Therapeutics reported a quarterly loss of $0.09 per share, missing the Zacks Consensus Estimate of a loss of $0.04, and compared to earnings of $0.07 per share a year ago, representing an earnings surprise of -125.00% [1] - The company posted revenues of $5.96 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 53.43%, and down from $33.43 million year-over-year [2] - The stock has increased approximately 308.7% since the beginning of the year, significantly outperforming the S&P 500's gain of 15.6% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.04 on revenues of $13.22 million, and for the current fiscal year, it is $0.05 on revenues of $95.6 million [7] - The estimate revisions trend for CytomX Therapeutics was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which CytomX Therapeutics belongs, is currently in the top 41% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]